WASHINGTON, March 4, 2026, 07:18 EST
- The FDA called out Ozempic over a consumer advertisement it says contained false or misleading claims, indicating the drug outperformed other GLP-1s.
- Novo Nordisk is taking action after regulators called out its advertising again—this marks the second warning in under a month.
- After the FDA ramped up scrutiny of GLP-1 marketing, telehealth firms pushing compounded versions have landed in regulators’ sights too.
Novo Nordisk A/S has been flagged again by the U.S. Food and Drug Administration, which says a consumer ad for its diabetes star, Ozempic, overstates the drug’s benefits and misleads viewers. It’s the Danish company’s second warning about its advertising in less than a month.
The change strikes at Novo’s core. Ozempic and Wegovy are central to the company’s U.S. ambitions, and marketing has been crucial as rivals crowd the space. Altering the pitch now runs the risk of muddling things further for patients and doctors already sorting through a tangle of options.
The FDA is tightening its grip on prescription drug marketing after President Donald Trump called for more oversight into how pharmaceutical companies promote their products. Drugmakers now face an increased chance that aggressive comparisons or broad claims will draw faster regulatory attention.
In a Feb. 26 letter, the regulator alleged Novo misrepresented Ozempic’s approved use in an online ad. The letter also pointed to language that, according to the regulator, suggested Ozempic outperformed other GLP‑1 drugs for type 2 diabetes. GLP‑1 therapies mimic the gut hormone glucagon-like peptide‑1 to manage blood sugar and, in some cases, reduce appetite.
The FDA took issue with the commercial, saying it implied Ozempic was suitable for every type 2 diabetes patient, even though its approvals are narrower—some uses apply only to those with heart disease or chronic kidney conditions. Regulators also didn’t like the ad’s humor; in particular, a joke comparing Ozempic to other GLP-1 drugs got flagged for hinting competitors weren’t worth much.
Novo’s been told by the agency to send a written response within 15 working days of getting the letter, flag any other comparable ads, and explain how it will remove them. Failing that, it must halt distribution of Ozempic altogether.
Novo is dealing with questions from regulators. “We take all regulatory feedback seriously and are in the process of responding to the FDA,” said spokesperson Liz Skrbkova. She added that the company received an “untitled letter”—that’s how the FDA refers to a notice outlining alleged promotional violations.
The regulator said the Ozempic notice followed an earlier FDA letter, dated Feb. 5, that flagged issues with a TV ad for Novo’s obesity treatment Wegovy.
On Tuesday, the FDA fired off warning letters to 30 telehealth firms it says are pitching compounded GLP‑1 drugs—pharmacy-mixed formulations—as if they’re legitimate alternatives to approved therapies. “It’s a new era of enforcement,” FDA Commissioner Marty Makary said, warning companies against positioning compounded products as substitutes for sanctioned treatments. Reuters
The FDA flagged telehealth firms in letters focused on compounded semaglutide, the core ingredient in Ozempic and Wegovy, as well as tirzepatide, which is used in Eli Lilly’s Zepbound and Mounjaro.
An FDA “untitled letter” points out problems that a company has to address, though it’s not as severe as a “warning letter” and doesn’t include a direct threat of enforcement. The agency also notes there’s no legal obligation to give companies a heads-up before taking enforcement action—so relying on any grace period is risky. U.S. Food and Drug Administration
